Navigation Links
Cellectis and the Etablissement Francais du Sang Launch StemRed, a Program to Produce Red Blood Cells From Stem Cells
Date:3/8/2011

PARIS, March 8, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the genome engineering specialist, and Etablissement Francais du Sang (EFS), the only civilian blood transfusion service in France, announce that StemRed, an ambitious collaborative program to produce red blood cells from induced pluripotent stem cells (iPS cells) has started on March 1.

This program, which also involves Pierre and Marie Curie University (UPMC), Bertin Technologies and CECS (Centre d'Etude des Cellules Souches), will run for a period of 7 years. It will receive funding of euro 9.3 million from OSEO, which provides financial support for innovative French companies, through its Industrial Strategic Innovation Program. This support is contingent upon the achievement of certain pre-established milestones.

"StemRed's main goal is to produce these cultured red blood cells on a large scale," said Professor Luc Douay of UPMC and CSO of EFS Ile de France, who pioneered this work.

"In the short term, these red blood cells may help improve the treatment of patients with a rare blood group, or receiving repeated transfusions and posing complex transfusion problems," added Professor Gerard Tobelem, President of EFS.

"Cellectis and EFS will develop and commercialize cultured red blood cells in the framework of equal partnership," explained Dr. David Sourdive, Executive Vice-President for Corporate Development at Cellectis and CEO of Ectycell, a Cellectis subsidiary for industrial applications of iPS cells(1).

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com.

Follow Cellectis on Twitter at www.Twitter.com/Cellectis.

About Etablissement Francais du Sang

Non-for-profit public structure that rely on voluntary blood donation, Etablissement Francais du Sang was established in 2000.

Under the supervision of the French Ministry of Health, its main mission is to provide blood products for the whole territory. Further to its core activity, EFS develops therapeutic activities and research programs to bring scientific and medical progress to the patient. EFS has 9,700 employees.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) Induced pluripotent stem cells, obtained from adult cells that have been reprogrammed to behave like embryonic stem cells


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
2. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection
3. Cellectis bioresearch Announces the First TGCA Winner
4. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
5. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
6. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
7. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
8. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
9. Cellectis Unveils Its New Corporate Website
10. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
11. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
Breaking Biology News(10 mins):